Back to Top

PAN Foundation Offers New Hope to Patients Fighting Genitourinary Cancers

 

Washington, DC, August 2, 2013 – In our quest to expand Patient Access Network’s charitable mission, the Foundation has launched a new financial assistance program for patients who are struggling to pay for their out-of-pocket costs related to their immunotherapies for Genitourinary Cancers. Immunotherapy treatments, considered breakthrough, personalized medicine, are presenting major affordability challenges which PAN, through its financial assistance programs, hopes to address.

“As treatment options become more personalized, patients are finding themselves unable to cover the out-of-pocket costs associated with these breakthrough, high-cost treatments,” explained Patrick McKercher, PAN President. “PAN is dedicated to removing financial barriers to care for patients seeking the most advanced treatments available. This program covers existing immunotherapies and will cover all forthcoming genitourinary cancer immunotherapies as they become available,” McKercher continued.

Qualifying patients are eligible to receive up to $10,000 per year to cover costs associated with their immunotherapy treatments. Patients must have insurance that covers the treatment for which they are seeking assistance, must have a household income less than or equal to 500% of the Federal Poverty Level and must reside and receive treatment in the United States.

About Metastatic Kidney Cancer (Renal Cell Carcinoma)

MRCC is the spread of the primary renal cell carcinoma from the kidney to other organs. 25-30% of sufferers have this metastatic spread by the time they are diagnosed with renal cell carcinoma. This high proportion is explained by the fact that clinical signs are generally mild until the disease progresses to a more severe state. The most common sites for metastasis are the lymph nodes, lung, bones, liver and brain. MRCC has a poor prognosis compared to other cancers although average survival times have increased in the last few years due to treatment advances.

About Metastatic Castrate Resistant Prostate Cancer

CRPC occurs when prostate cancer has metastasized to other parts of the body (generally the bones), and is no longer responding to hormone treatment or gets worse on hormone therapy. Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40. People who are at a higher risk include: African-American men, men who are older than 60, men who have a father or brother with prostate cancer and those who have particular inherited genetic predisposition to the disease.

About the PAN Foundation

Patient Access Network Foundation is dedicated to providing help and hope to patients who would otherwise be unable to afford high-cost specialty medications. PAN envisions a society in which every individual can access needed medical care, offering hope for a healthy tomorrow. PAN provides assistance through more than 50 disease-specific programs designed to help patients being treated for certain cancers, chronic illnesses, and rare diseases. Through our streamlined application process and state of the art online tools, we are able to ensure that patients are put on the fast track to therapy.